Safety of the Methacholine Challenge Test in Patients with Severe Airway Obstruction

Pai-Chien Chou, Chi-Lan Lin, Wen-Te Liu, Horng-Chyuan Lin, Han-Pin Kuo

Research output: Contribution to journalArticle

Abstract

Airway hyperresponsiveness (AHR) is defined as an increased sensitivity to bronchoconstrictor stimuli. It is regarded as the physiological hallmark of bronchial asthma. The methacholine challenge test has proved to be helpful in the diagnosis of asthma and the evaluation of AHR. The aim of this study was to investigate the safety of the methacholine challenge test among patients with low FEV1, who posed a substantial risk for deterioration of airway obstruction. We retrospectively investigated 241 asthmatic patients who had an initial FEV1 less than 1L and who underwent a methacholine challenge test (initial FEV1: 0.77±0.15L, 38.8±11.6% of predicted value; PC20: 3.1±4.6 mg/ml). Among the 241 asthmatic patients with FEV1<1L, 108 (44.8%) had full post-challenge reversibility after b2 agonist inhalation. In contrast, only 58 controls with FEV1>1L (22%) had significant postchallenge reversibility. The degree of post-challenge reversibility in asthmatic patients with FEV1< 1L was significantly inversely correlated with the initial FEV1 and the end FEV1 after a methacholine challenge. There were no major respiratory complications related to the methacholine challenge test. Thus, the methacholine challenge test is relatively safe but potentially dangerous in patients with severe airway obstruction. The patient’s condition should be monitored closely during the test, and a bronchodilator should be used to reverse the airway obstruction related to the methacholine challenge.
Original languageEnglish
Pages (from-to)329-337
Number of pages9
Journal胸腔醫學
Volume18
Issue number4
Publication statusPublished - Aug 1 2003
Externally publishedYes

Fingerprint

Methacholine Chloride
Airway Obstruction
Safety
Asthma
Bronchoconstrictor Agents
Bronchodilator Agents
Inhalation

Keywords

  • Methacholine challenge
  • FEV1
  • asthma

Cite this

Safety of the Methacholine Challenge Test in Patients with Severe Airway Obstruction. / Chou, Pai-Chien; Lin, Chi-Lan; Liu, Wen-Te; Lin, Horng-Chyuan; Kuo, Han-Pin.

In: 胸腔醫學, Vol. 18, No. 4, 01.08.2003, p. 329-337.

Research output: Contribution to journalArticle

@article{7c3404b6a41c4c918d13d14248800b1a,
title = "Safety of the Methacholine Challenge Test in Patients with Severe Airway Obstruction",
abstract = "Airway hyperresponsiveness (AHR) is defined as an increased sensitivity to bronchoconstrictor stimuli. It is regarded as the physiological hallmark of bronchial asthma. The methacholine challenge test has proved to be helpful in the diagnosis of asthma and the evaluation of AHR. The aim of this study was to investigate the safety of the methacholine challenge test among patients with low FEV1, who posed a substantial risk for deterioration of airway obstruction. We retrospectively investigated 241 asthmatic patients who had an initial FEV1 less than 1L and who underwent a methacholine challenge test (initial FEV1: 0.77±0.15L, 38.8±11.6{\%} of predicted value; PC20: 3.1±4.6 mg/ml). Among the 241 asthmatic patients with FEV1<1L, 108 (44.8{\%}) had full post-challenge reversibility after b2 agonist inhalation. In contrast, only 58 controls with FEV1>1L (22{\%}) had significant postchallenge reversibility. The degree of post-challenge reversibility in asthmatic patients with FEV1< 1L was significantly inversely correlated with the initial FEV1 and the end FEV1 after a methacholine challenge. There were no major respiratory complications related to the methacholine challenge test. Thus, the methacholine challenge test is relatively safe but potentially dangerous in patients with severe airway obstruction. The patient’s condition should be monitored closely during the test, and a bronchodilator should be used to reverse the airway obstruction related to the methacholine challenge.",
keywords = "Methacholine challenge, FEV1, asthma, 激發試驗, 第一秒吐氣量, 氣喘",
author = "Pai-Chien Chou and Chi-Lan Lin and Wen-Te Liu and Horng-Chyuan Lin and Han-Pin Kuo",
year = "2003",
month = "8",
day = "1",
language = "English",
volume = "18",
pages = "329--337",
journal = "胸腔醫學",
issn = "1023-9855",
publisher = "臺灣胸腔暨重症加護醫學會",
number = "4",

}

TY - JOUR

T1 - Safety of the Methacholine Challenge Test in Patients with Severe Airway Obstruction

AU - Chou, Pai-Chien

AU - Lin, Chi-Lan

AU - Liu, Wen-Te

AU - Lin, Horng-Chyuan

AU - Kuo, Han-Pin

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Airway hyperresponsiveness (AHR) is defined as an increased sensitivity to bronchoconstrictor stimuli. It is regarded as the physiological hallmark of bronchial asthma. The methacholine challenge test has proved to be helpful in the diagnosis of asthma and the evaluation of AHR. The aim of this study was to investigate the safety of the methacholine challenge test among patients with low FEV1, who posed a substantial risk for deterioration of airway obstruction. We retrospectively investigated 241 asthmatic patients who had an initial FEV1 less than 1L and who underwent a methacholine challenge test (initial FEV1: 0.77±0.15L, 38.8±11.6% of predicted value; PC20: 3.1±4.6 mg/ml). Among the 241 asthmatic patients with FEV1<1L, 108 (44.8%) had full post-challenge reversibility after b2 agonist inhalation. In contrast, only 58 controls with FEV1>1L (22%) had significant postchallenge reversibility. The degree of post-challenge reversibility in asthmatic patients with FEV1< 1L was significantly inversely correlated with the initial FEV1 and the end FEV1 after a methacholine challenge. There were no major respiratory complications related to the methacholine challenge test. Thus, the methacholine challenge test is relatively safe but potentially dangerous in patients with severe airway obstruction. The patient’s condition should be monitored closely during the test, and a bronchodilator should be used to reverse the airway obstruction related to the methacholine challenge.

AB - Airway hyperresponsiveness (AHR) is defined as an increased sensitivity to bronchoconstrictor stimuli. It is regarded as the physiological hallmark of bronchial asthma. The methacholine challenge test has proved to be helpful in the diagnosis of asthma and the evaluation of AHR. The aim of this study was to investigate the safety of the methacholine challenge test among patients with low FEV1, who posed a substantial risk for deterioration of airway obstruction. We retrospectively investigated 241 asthmatic patients who had an initial FEV1 less than 1L and who underwent a methacholine challenge test (initial FEV1: 0.77±0.15L, 38.8±11.6% of predicted value; PC20: 3.1±4.6 mg/ml). Among the 241 asthmatic patients with FEV1<1L, 108 (44.8%) had full post-challenge reversibility after b2 agonist inhalation. In contrast, only 58 controls with FEV1>1L (22%) had significant postchallenge reversibility. The degree of post-challenge reversibility in asthmatic patients with FEV1< 1L was significantly inversely correlated with the initial FEV1 and the end FEV1 after a methacholine challenge. There were no major respiratory complications related to the methacholine challenge test. Thus, the methacholine challenge test is relatively safe but potentially dangerous in patients with severe airway obstruction. The patient’s condition should be monitored closely during the test, and a bronchodilator should be used to reverse the airway obstruction related to the methacholine challenge.

KW - Methacholine challenge

KW - FEV1

KW - asthma

KW - 激發試驗

KW - 第一秒吐氣量

KW - 氣喘

M3 - Article

VL - 18

SP - 329

EP - 337

JO - 胸腔醫學

JF - 胸腔醫學

SN - 1023-9855

IS - 4

ER -